Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

April 6, 2018: By Jon Swedien

A first-in-kind stem cell–based retinal implant improved visual acuity or function in three of four subjects with advanced dry age-related macular degeneration (AMD) during a Phase I/IIa study, according to physicians and researchers at the USC Roski Eye Institute.

The treatment consisted of a layer of human embryonic stem cell-derived retinal pigment epithelium cells on an ultrathin supportive structure implanted in the retina, the university said. A USC Roski Eye Institute surgeon performed the surgeries on the four patients.

The treatment is designed to replace a single-cell layer that degenerates in patients with dry AMD, said lead author and surgeon for the study, Amir H. Kashani, MD, PhD.

Researchers followed the study’s four patients for up to one year to assess the implant’s safety. There were no severe adverse events related to the implant or the surgical procedure, the university said.

The research team also performed a preliminary assessment of the therapy’s efficacy.

One patient’s visual acuity improved by 17 letters. Two patients gained visual function, as measured by how well they could use the area of the retina treated by the implant, the university said.

None of the patients’ vision worsened, the university said. Researchers noted integration of the implant with photoreceptor cells in all patients.

The study results were published April 4 in Science Translational Medicine.

The study is titled “A Bioengineered Retinal Pigment Epithelial Monolayer for Advanced Dry Age Related-Macular Degeneration.”

It was funded in part by the California Institute for Regenerative Medicine, the university said. Regenerative Patch Technologies also contributed funding to the study.

Mark Humayun, MD, PhD, is the coauthor and lead inventor of the implant. Humayun also co-invented and co-developed the Argus II Retinal Prosthesis System with Second Sight Medical Products.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023